Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Motor Activity 1

Interventions

Paclitaxel 152Carboplatin 123Bevacizumab 86Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 38Topotecan 37olaparib 30Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20Platinum 19niraparib 18Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fitness Trackers × Gynecologic × Clear all
NCT03364673 2023-10-13

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

Dana-Farber Cancer Institute

Phase NA Completed
29 enrolled 16 charts
Gynecologic

Motor Activity, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡